^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/28/2020
Excerpt:
Pediatric Hodgkin Lymphoma...Re-Induction Therapy Options...Brentuximab Vedotin+nivolumab...Hodgkin lymphoma: Second-line options…Brentuximab vedotin + nivolumab
